Increased Mitochondrial DNA Content in Saliva Associated with Head and Neck Cancer

Wei-Wen Jiang,1 Brett Masayesva,1 Marianna Zahrak,2 Andre Lopes Carvalho,3 Eli Rosenbaum,3 Elizabeth Mambo,1 Shaoyu Zhou,1 Khalid Minhas,1 Nicole Benoit,1 William H. Westra,4 Anthony Alberg,5 David Sidransky,1 Wayne Koch,1 and Joseph Califano1

Abstract

Alterations of the mitochondrial DNA (mtDNA) have been described in human tumors and in other tissues in association with smoking exposure. We did quantitative PCR of cytochrome c oxidase I (Cox I) and cytochrome c oxidase II (Cox II) genes on oral rinse samples obtained from 94 patients with primary head and neck squamous cell carcinoma (HNSC) and a control group of 656 subjects. Mitochondrial DNA/nuclear DNA in saliva from HNSC patients and controls in relationship to smoking exposure, ethanol intake, and tumor stage were examined. Mean levels of Cox I and Cox II in saliva samples were significantly higher in HNSC patients: Cox I, 0.076 [95% confidence interval (95% CI), 0.06-0.09] and Cox II, 0.055 (95% CI, 0.04-0.07) in comparison with controls Cox I, 0.054 (95% CI, 0.05-0.06), P < 0.0001 and Cox II, 0.046 (95% CI, 0.04-0.05), P = 0.003 (t test). MtDNA levels were elevated in primary tumors when compared with matched, pretreatment saliva and significant correlation was noted (Cox I, r = 0.30, P = 0.005 and Cox II, r = 0.33, P = 0.002, respectively, Pearson’s correlation). On univariate analysis, smoking, age, HNSC diagnosis, and advanced stage of HNSC were associated with higher level of mtDNA content in saliva. Multivariate analysis showed a significant and independent association of HNSC diagnosis, age, and smoking with increasing mtDNA/nuclear DNA for Cox I and Cox II. mtDNA content alteration is associated with HNSC independently of age and smoking exposure, can be detected in saliva, and may be due to elevation in mtDNA content in primary HNSC.

Mitochondria are an important biological source and target of reactive oxygen species and free radicals and are sensitive to environmental mutagens, including tobacco smoke. Normal assembly and operation of the respiratory chain requires an intact and functional mitochondrial genome. The functional complement of mitochondrial DNA (mtDNA) in a cell depends on both the copy number of mitochondrial genomes as well as the integrity of each mtDNA molecule (1). The number of mitochondria per cell type is highly variable depending on the cell’s energetic demand (2). Any event invalidating the respiratory chain, either issuing from genetic damage or from the cell environment (3) could provide a proliferating advantage to a transformed or tumor cell.

During the past few years, point mutation or length instability of displacement loop and Coding region, 4,977 deletion or short deletion of mitochondria have been found involved in the colorectal (4, 5), breast (6), gastric (7), renal (8), esophageal (9), thyroid cancer (10), and head and neck cancer (11). Furthermore, the increase of mtDNA content with age has been hypothesized to be a compensatory response for the decline in respiratory function (12).

On the other hand, there are over 3,800 compounds in cigarette smoke, including a large amount of mutagenic and oxygen radical-forming substances and over 60 documented carcinogens. These organic radicals and genotoxic agents may cause extensive damage to DNA, proteins, and lipids (13). Evidence concerning a connection between smoking and head and neck cancer has been extensively documented (14). Recently, mtDNA content was identified to be altered in aging and smoking-associated lung tissue (15). We hypothesized that elevation in salivary mtDNA associated with development of head and neck squamous cell carcinoma (HNSC) is independent of other factors that may contribute to mtDNA increase and determined associations with other clinicopathologic variables.

To test these hypotheses, we did quantitative PCR of mtDNA content (Cox I and Cox II) on oral rinse samples obtained from 94 of primary HNSC subjects and a control group of 656 participants without HNSC, examining known risk factors for HNSC development, mtDNA content alteration, and clinical variables associated with HNSC.
Materials and Methods

**Subjects.** Ninety-four oral rinse samples were collected from patients with primary HNSC at Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Johns Hopkins University, after appropriate approval was obtained from the Johns Hopkins institutional review board. We also obtained control oral rinse samples from 656 non-HNSC subjects with a variety of ages and risk factors, including smoking and alcohol intake, were recruited for a head and neck screening study. All control subjects were given a confidential survey of risk factors for head and neck cancer (alcohol, tobacco use, etc.) as well as the presence of comorbid illness. Smoking was defined as at least one continuous year of daily smoking. Data regarding tobacco exposure and ethanol intake from HNSC subjects was abstracted from hospital records.

**Collection of oral rinse samples.** Oral rinse samples were obtained by swishing and gargling for 15 seconds with 25 mL of sterile 0.9% NaCl and brushing oral and oropharyngeal mucosal surfaces with an exfoliative brush and rinsing in the salt solution. The 25-mL swish and gargle samples were subjected to centrifugation at 2,500 rpm for 15 minutes. The supernatant was discarded, and the cell pellet was retained and placed in 1% SDS/proteinase K (0.5 mg/mL) at 48°C for 72 hours. Digested product was then subjected to phenol-chloroform extraction and ethanol precipitation.

**Quantitative PCR.** A Perkin-Elmer/ABI 7900 thermocycler was used to perform quantitative PCR amplification for β-actin, mtDNA regions for cytochrome c oxidase I (Cox I) and cytochrome c oxidase II (Cox II). Primers were custom made and obtained from Invitrogen (Carlsbad, CA). The Cox I region was amplified using forward primer 5'-TTCGCCGACCGTTGAATCTCTC-3' and reverse primer 5'-AAGATATTACAAATTGACAGGC. Cox II region amplification was done using forward primer 5'-CCCCACATTAGGCTTAAAAACAGAT-3' and reverse primer 5'-TATACCCCCGTCTGTAGGC-3'. β-Actin amplification was done using

### Table 1. Characteristics of HNSC subjects and controls

<table>
<thead>
<tr>
<th></th>
<th>HNSC (%)</th>
<th>Control (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>71 (75.5)</td>
<td>413 (63.3)</td>
<td>0.0197</td>
</tr>
<tr>
<td>Female</td>
<td>23 (24.5)</td>
<td>240 (36.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Age (y)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>56.8</td>
<td>61.8</td>
<td>0.0008</td>
</tr>
<tr>
<td>Median</td>
<td>57</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>31-85</td>
<td>18-94</td>
<td></td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>70 (75.3)</td>
<td>510 (78.5)</td>
<td>0.4865</td>
</tr>
<tr>
<td>Other</td>
<td>23 (24.7)</td>
<td>140 (21.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>19 (20.9)</td>
<td>248 (38.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Former</td>
<td>24 (26.4)</td>
<td>326 (49.9)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>48 (52.8)</td>
<td>79 (12.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Ethanol</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>30 (39.0)</td>
<td>124 (20.6)</td>
<td>0.0012</td>
</tr>
<tr>
<td>Former</td>
<td>13 (16.9)</td>
<td>115 (19.1)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>34 (44.2)</td>
<td>364 (60.4)</td>
<td></td>
</tr>
<tr>
<td><strong>mtDNA(natural scale)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cox I</td>
<td>0.076</td>
<td>0.054</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cox II</td>
<td>0.055</td>
<td>0.046</td>
<td>0.003</td>
</tr>
</tbody>
</table>

NOTE: Race distribution is similar in two groups. Gender, age, smoking, and ethanol intake have different distribution between two groups.
forward primer 5'-ACCCACACTGTGCCCATCTAC-3' and reverse primer 5'-TCGGTGAGGATCTTCATGAGGTA-3'. All Taqman probes (Applied Biosystems, Foster City, CA) were 5'-FAM and 3'-TAMRA labeled. Cox I probe 6-FAM-AACGACCACATCTACAACGTTATCGTCAC-TAMRA, Cox II probe 6-FAM-CAATTCCCGGACGTCTAAACCAAACCACTTC-TAMRA, and b-actin probe 6-FAM-ATGCCCTCCCCCATGCCATCC-TAMRA were used. Five hundred picograms of DNA were used to amplify mitochondrial regions, whereas 10 ng were used to amplify b-actin. The real-time PCR reactions were done in triplicate for each gene. Standard curves where obtained using adult retinal pigmented epithelia 19 cell line DNA from untreated control cells. mtDNA/nuclear DNA (nDNA) ratios were calculated by dividing the mtDNA signal for each gene by the corresponding b-actin signal. Of note, primers were chosen to avoid amplification of genomic pseudogenes that are homologous to mitochondrial genes, this was confirmed by BLAST results for all primers (http://www.ncbi.nlm.nih.gov/BLAST/). In addition, to exclude the possibility that random nicking due to tobacco use may lead to an apparent increase in amplification of these shorter targets, we treated 100 matched samples from subjects with varied smoking exposures with and without PvuII digestion to linearize mtDNA before amplification and noted no difference in the smoking-related increase in mtDNA/nDNA. Finally, mtDNA content was compared with mitochondrial mass as measured by amount of Cox II protein within samples by performing Western blot analysis on samples with a variety of mtDNA/nDNA ratios, demonstrating excellent agreement between mtDNA content and Cox II protein normalized to b-actin controls.

**Statistical analysis.** The major statistical end point in this study was the comparison of mean mtDNA content in normal versus HNSC saliva specimens and the effects of age, gender, smoking, and ethanol intake on these means. Within HNSC patients, mtDNA content by tumor stage and site was also compared. Distribution of mtDNA/nDNA values were examined graphically with box plots and scatter plots, on the natural and log scales. To obtain normal distribution, the log transformation was used for all statistical analyses, whereas means and SDs are reported on the natural scales. Two or more group means were compared with an analysis of variance and the relationship between the logarithm of mtDNA and multiple factors was evaluated by regression analyses. The correlation between saliva and tissue mtDNA was also of interest. Scatter plots and Pearson product-moment correlation coefficients were computed between age and mtDNA content and between saliva and tissue mtDNA values. All statistical computations were done using the SAS system and all Ps are two sided.

### Table 2. mtDNA content (natural scale) in saliva samples with smoking status

<table>
<thead>
<tr>
<th>Subjects</th>
<th>mtDNA content</th>
<th>Smoking</th>
<th>n</th>
<th>Mean</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>Cox I</td>
<td>Never</td>
<td>248</td>
<td>0.043</td>
<td>0.03-0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Former</td>
<td>325</td>
<td>0.059</td>
<td>0.05-0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Current</td>
<td>79</td>
<td>0.066</td>
<td>0.05-0.09</td>
</tr>
<tr>
<td></td>
<td>Cox II</td>
<td>Never</td>
<td>248</td>
<td>0.037</td>
<td>0.03-0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Former</td>
<td>326</td>
<td>0.051</td>
<td>0.04-0.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Current</td>
<td>79</td>
<td>0.051</td>
<td>0.04-0.06</td>
</tr>
<tr>
<td>HNSC</td>
<td>Cox I</td>
<td>Never</td>
<td>19</td>
<td>0.074</td>
<td>0.04-0.10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Former</td>
<td>24</td>
<td>0.076</td>
<td>0.05-0.10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Current</td>
<td>48</td>
<td>0.075</td>
<td>0.05-0.10</td>
</tr>
<tr>
<td></td>
<td>Cox II</td>
<td>Never</td>
<td>19</td>
<td>0.058</td>
<td>0.04-0.08</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Former</td>
<td>24</td>
<td>0.049</td>
<td>0.03-0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Current</td>
<td>48</td>
<td>0.06</td>
<td>0.04-0.08</td>
</tr>
</tbody>
</table>

Fig. 2. Box plots of mtDNA content stratified by cancer diagnosis and smoking. Cox I (A) and Cox II (B) show that the smoking related increase in mtDNA are limited to the noncancer controls. *, \( P_{ \text{Cox } I} = 0.002 \) and \( P_{ \text{Cox } II} = 0.011 \) in the never-smoker saliva between HNSC Cox I, 0.074 (95% CI, 0.044-0.104) and Cox II, 0.058 (95% CI, 0.037-0.080) and controls Cox I, 0.043 (95% CI, 0.034-0.051) and Cox II, 0.037 (95% CI, 0.030, 0.043). **, \( P = 0.016 \) of the former-smoker saliva between HNSC Cox I, 0.076 (95% CI, 0.050-0.103) and control Cox I, 0.059 (95% CI, 0.050-0.069). No significant difference in salivary mtDNA content was found for current smokers between HNSC and control.
Results

Mitochondrial DNA content in saliva of head and neck squamous cell carcinoma and control group. We did quantitative PCR of normalized Cox I and Cox II genes in the saliva of 94 HNSC patients and 656 controls. Table 1 shows the baseline characteristics of the study participants. Race distribution was similar in two groups. Seventy-five percent of the HNSC cohort was male, 63.3% in controls. Current drinkers comprised 44.2% (34 of 77) of the HNSC, a significantly lower proportion than that 60.4% (364 of 603) of the control. HNSC patients had more current smokers (52.8%) than the control (12.1%). The mean age in the HNSC group, 57 years (95% CI), 54-59 was significantly younger that the mean age in the control group of 62 years (95% CI, 61-63; \( P = 0.0008 \)). Mean content levels of Cox I and Cox II in saliva samples were significantly higher in HNSC patients compared with normal controls (Fig. 1).

Saliva and tissue mitochondrial DNA content are correlated. For 86 HNSC patients, paired primary tumor and pretreatment saliva were evaluated. A significant correlation was noted between mtDNA content in saliva and that in matching primary tumor (Cox I \( r = 0.30 \), \( P = 0.005 \) and Cox II \( r = 0.33 \), \( P = 0.002 \); Pearson’s correlation). The mtDNA ratio was elevated in primary tumors in comparison with levels in matching saliva.

Head and neck squamous cell carcinoma is an independent predictor of elevated mitochondrial DNA in saliva. Using a univariate regression model, we analyzed possible factors associated with increased mtDNA content, including HNSC diagnosis, smoking, ethanol, age, and gender. We found that age, HNSC diagnosis, and smoking were significantly associated with increased mtDNA. Overall, increasing age was significantly associated with higher levels of mtDNA (Cox I: slope = 0.01; 95% CI, 0.007-0.019; \( P < 0.0001 \)) and (Cox II: slope = 0.007; 95% CI, 0.001-0.013; \( P = 0.01 \)). Of note, this age-related mtDNA content increase was not significant in the saliva of HNSC group. Table 2 shows mtDNA content with different smoking status in HNSC and control. Comparing with never smoker, average Cox I (\( P_{\text{current}} < 0.0001 \), \( P_{\text{former}} = 0.01 \)) and Cox II (\( P_{\text{current}} < 0.0001 \), \( P_{\text{former}} = 0.02 \)) content significantly increased with smoking category in the overall saliva samples. To determine whether each smoking category affects the mtDNA content in the saliva of HNSC differently from that does in the control, we compared Cox I and Cox II DNA content of never smokers, former smokers, and current smokers in the HNSC and control. Box

![Figure 1](image1.png)

![Figure 2](image2.png)

![Figure 3](image3.png)

Table 3. Multivariate regression model for log (Cox)

<table>
<thead>
<tr>
<th>Variable</th>
<th>mtDNA content</th>
<th>95% CI</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept Cox I</td>
<td>-5.03 to -4.29</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.01-0.02</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>HNSC</td>
<td>0.28-0.78</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>Former smoker</td>
<td>0.19-0.66</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>0.001-0.34</td>
<td>0.0004</td>
<td></td>
</tr>
<tr>
<td>Intercept Cox II</td>
<td>-4.65 to -3.96</td>
<td>0.022</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.003-0.01</td>
<td>0.022</td>
<td></td>
</tr>
<tr>
<td>HNSC</td>
<td>0.08-0.55</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Former smoker</td>
<td>0.16-0.60</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>-0.003 to 0.31</td>
<td>0.001</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Multivariate regression model was used to adjust for more than one factor at a time, including significant factors found on univariate analysis: HNSC diagnosis, smoking, and age.
plots (Fig. 2) of mtDNA content levels by HNSC diagnosis and smoking categories show that the increases by smoking category are limited to normal controls. We also found mtDNA content greatly increased in the saliva of never-smoker HNSC patients when compared with that of normal control but found no significant difference in the current-smokers saliva between saliva from current smoker HNSC patients and current smokers in the control group. Furthermore, we used a multivariate regression model to adjust for more than one factor at a time, including significant factors found on univariate analysis (HNSC diagnosis, smoking, and age) remaining significant factors influencing mtDNA content. Neither ethanol intake nor gender was independently associated with mtDNA content (Table 3).

**Tumor stage associated with increased mitochondrial DNA content.** To assess the alteration of mtDNA content on tumor stage, we examined the relative content of Cox I and Cox II in saliva from the early stage (stages I and II) versus advanced stage (stages III and IV) HNSC. The results showed a significant increased mtDNA content in the saliva with advanced stage (Fig. 3). Cox I of early stage in HNSC saliva was 0.048 (95% CI, 0.03-0.07) and advance stage, 0.086 (95% CI, 0.07-0.11), P = 0.03. Cox II of early stage was 0.029 (95% CI, 0.02-0.04) and advance stage, 0.063 (95% CI, 0.05-0.08), P = 0.04.

Within the HNSC group, tumor site was also associated with significant differences in mtDNA/nDNA, demonstrating an increase for salivary rinse Cox I in the oropharynx, 0.098 (95% CI, 0.07-0.13; P = 0.006) and hypopharynx groups. The small number of patients in the hypopharynx group (n = 4) limits the conclusions that can be drawn about this group, however.

**Discussion**

We found that mtDNA content (Cox I and Cox II) in the saliva from HNSC patients is elevated in comparison with the saliva from normal control saliva, independent of age, smoking status, and other possible confounding variables. Mitochondrial alterations have long been suspected as contributes to carcinogenesis (16). Previous studies showed that the increased mtDNA in human cells harboring 4,977 bp deleted mtDNA in response to oxidative stress (17). In addition, mitochondrial genomic mutations have been found in HNSC (11). It is possible that the increase on content of mtDNA may be a compensatory response for the decline in respiratory function, as has been described in vitro systems. The association of elevated salivary mtDNA content with advanced stage HNSC, as well as the correlation of increased salivary mtDNA with increased mtDNA in individual primary tumors also supports the concept that this is a reflection of mtDNA alteration in cells shed from primary tumors in the upper aerodigestive tract.

The higher mtDNA content in the current smokers, particularly in control subjects, may be explained by multiple factors. Tobacco smoke is one of the exogenous sources which may significantly increase direct mutagenic effects on mtDNA as well as the endogenous oxidant load via injury to the respiratory chain (13, 18, 19). The increase in reactive oxygen species production from a defective respiratory chain is thought to play a role in the increase of mitochondrial mass and mtDNA content (20, 21). Furthermore, both the reactive oxygen species and Ca2+ may act as the second messengers to trigger the expression of nuclear respiratory factors (NRF-1 and NRF-2) and mitochondrial transcription factors to induce mitochondrial biogenesis and mitochondrial proliferation (20–22).

Interestingly, the content of mtDNA in saliva from current smokers with HNSC comparing with nonsmokers with HNSC showed no significant difference. It is possible that this is due to a compensatory increase in mtDNA replication due to factors directly related to or present in primary HNSC in nonsmokers, and that elevated mtDNA in saliva of nonsmokers with HNSC is related to the increase in mtDNA from shed tumor cells or from altered fields of mucosa with mtDNA alteration.

It is worth noting that increased mitochondrial production of reactive oxygen species (23), oxidation of mitochondrial proteins (24), depressed oxidative phosphorylation activity (25), and disrupted fatty acid metabolism (26) occur in the liver following consumption of alcohol. One objective of our study was to evaluate and compare the possible role of ethanol intake on mtDNA content alteration in HNSC and control saliva. Our simple linear regression and multivariate regression model indicated that ethanol intake did not have an independent role on alterations of mtDNA content. However, we were unable to effectively segregate the smoking and ethanol exposures, and were not able to exclude whether effect of ethanol on mtDNA content in HNSC saliva independent of smoking. It is possible that underreporting of ethanol by our HNSC population as compared with our control population may have influenced (i.e. underestimated) the effect of ethanol on relative increase of mtDNA. However, we did not observe an association of ethanol intake with increased mtDNA within our control population, making this effect unlikely.

In this study, we provided novel evidence that elevated mtDNA does not only occur in the tobacco-exposed individuals without HNSC but also exists in the saliva of patients with HNSC, is independently associated with presence of HNSC, and is associated with advanced stage disease. Further investigation may elucidate the timing of mtDNA alteration in HNSC carcinogenesis and provide a mechanism for this increase in smoking and nonsmoking-related HNSC.

**Acknowledgments**

We thank the contributions of the Notre Dame Chapter of the Knights of Columbus of Maryland, Mount Pleasant Church and Ministries; the American Legion Department and Posts of Maryland; and the Veterans of Foreign Wars, Department of Maryland; and Maura Gillison, MD, PhD for help in survey design.

**References**


Increased Mitochondrial DNA Content in Saliva Associated with Head and Neck Cancer

Wei-Wen Jiang, Brett Masayesva, Marianna Zahurak, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/7/2486

Cited articles
This article cites 25 articles, 8 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/7/2486.full.html#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
/content/11/7/2486.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.